The first clinical trial of psilocybin in Parkinson’s disease found significant improvements in mood symptoms, suggesting potential efficacy in managing depression and anxiety. The treatment also seemed to benefit motor and nonmotor symptoms of PD with no significant safety concerns reported. Potential mechanisms include modulation of serotonergic signaling, anti-inflammatory activity, and promotion of neuroplasticity. However, the study’s limitations included a small sample size and lack of racial diversity, highlighting the need for further controlled trials.